DEA Hearing Record Signals Administrative Law Judge's Likely Ruling Path

Record Closure Marks End of Evidence Phase

The DEA's administrative law judge closed the evidentiary record for the marijuana rescheduling hearing on August 9, 2026, moving the proceeding into the post-hearing briefing phase. Weeks of testimony preceded the closure. Pharmacologists testified. So did clinicians, law enforcement officials, and industry representatives. According to the DEA's procedural rules, parties now have 30 days to submit post-hearing briefs before the ALJ issues a recommended decision to DEA Administrator Anne Milgram.

The record includes more than 4,000 pages of exhibits, expert declarations, and hearing transcripts. The DEA hasn't disclosed a timeline for the ALJ's recommended decision, but agency precedent suggests a ruling within 90 to 120 days of briefing closure.

Procedural Indicators Point Toward Schedule III Affirmation

Several procedural decisions by the ALJ during the hearing suggest a possible inclination to affirm HHS's August 2023 recommendation to reschedule marijuana to Schedule III. The judge admitted HHS's 252-page scientific review in full as Exhibit A without modification, a move that typically signals deference to the agency's medical and scientific findings under the Controlled Substances Act's five-factor test.

The ALJ also denied motions from Schedule I proponents to exclude testimony from FDA officials who participated in the HHS review, preserving the government's core evidentiary foundation. By contrast, the judge sustained objections to anecdotal patient testimonials offered by rescheduling opponents, which narrowed the admissible evidence to peer-reviewed studies and agency data.

HHS Five-Factor Analysis Anchors the Record

The HHS recommendation, based on the Controlled Substances Act's five-factor framework, concluded that marijuana has accepted medical use in treatment and a lower abuse potential than Schedule I or II substances. The analysis cited FDA-approved cannabinoid drugs, state medical cannabis programs serving more than 6 million registered patients, and pharmacological data showing cannabis doesn't produce the severe physical dependence characteristic of Schedule II opioids or stimulants.

HHS's abuse-potential determination rested on epidemiological studies showing that while cannabis dependence occurs, it's less severe and less common than dependence on Schedule II substances such as oxycodone or methamphetamine. The agency also noted that no fatal overdose cases have been attributed solely to cannabis, a factor the Controlled Substances Act directs agencies to weigh.

Opposition Testimony Focused on Youth Access and Impaired Driving

Witnesses opposing rescheduling, including representatives from Smart Approaches to Marijuana and the National Sheriffs' Association, argued that moving cannabis to Schedule III would increase youth access and complicate impaired-driving enforcement. Those witnesses didn't dispute HHS's medical findings. Instead, they emphasized policy consequences outside the five-factor statutory test.

Cross-examination revealed the ALJ's skepticism. Her questioning suggested doubt about whether policy concerns unrelated to abuse potential and medical use fall within the scope of the rescheduling analysis. Under the Controlled Substances Act, the Attorney General—acting through the DEA—must base scheduling decisions on the five factors, not broader social-policy considerations.

Section 280E Tax Implications Loom Over Industry

A Schedule III designation would allow state-licensed cannabis businesses to deduct ordinary business expenses under federal tax law, ending the application of Internal Revenue Code Section 280E, which currently prohibits deductions for businesses trafficking in Schedule I or II controlled substances. Industry analysts estimate that 280E repeal would reduce effective tax rates for multi-state operators from 70–80% to 25–30%, unlocking billions in retained earnings.

The tax question didn't feature prominently in the hearing testimony, as the Controlled Substances Act doesn't authorize the ALJ to consider tax policy. Still, the financial stakes have driven intense lobbying from both the cannabis industry and pharmaceutical manufacturers, who fear competition from rescheduled marijuana products.

Next Steps: Post-Hearing Briefs and ALJ Recommendation

Parties have until September 8, 2026, to file post-hearing briefs, with reply briefs due September 22. The ALJ will then issue a recommended decision to DEA Administrator Milgram, who retains final authority to accept, modify, or reject the recommendation. If Milgram accepts a Schedule III recommendation, the DEA must publish a final rule in the Federal Register, triggering a 30-day effective date and opening a window for judicial review in the U.S. Court of Appeals for the D.C. Circuit.

A final DEA rule could be published by late 2026 or early 2027, barring unforeseen delays or a decision to remand the matter for additional evidence. For full background on this story, see the CannIntel topic hub on the DEA rescheduling hearing.

The next signal will be the filing of post-hearing briefs by September 8. Until then, the record is frozen.